共 23 条
Bristol Stool Scale as a Determinant of Hepatic Encephalopathy Management in Patients With Cirrhosis
被引:13
作者:
Duong, Nikki K.
[1
,2
]
Shrestha, Shreesh
[1
,2
]
Park, Dan
[1
,2
]
Shahab, Omer
[1
,2
]
Fagan, Andrew
[1
,2
]
Malpaya, Zenaida
[1
,2
]
Gallagher, Mary L.
[1
,2
]
Morris, April
[1
,2
]
Davis, Brian C.
[1
,2
]
Bajaj, Jasmohan S.
[1
,2
]
机构:
[1] Virginia Commonwealth Univ, Richmond, VA 23284 USA
[2] Cent Virginia Vet Healthcare Syst, Richmond, VA 23249 USA
关键词:
FORM SCALE;
LACTULOSE;
D O I:
10.14309/ajg.0000000000001550
中图分类号:
R57 [消化系及腹部疾病];
学科分类号:
摘要:
INTRODUCTION: Bowel movement (BM) frequency is used to titrate lactulose for hepatic encephalopathy (HE). However, stool consistency using the Bristol stool scale (BSS, 0-7) is often ignored. METHODS: The study included pre-BSS and post-BSS cohorts. BSS was incorporated into decision-making after training in outpatients with cirrhosis. Two to 3 BMs/d and BSS 3-4 were considered normal, whereas the rest were considered high or low; concordance between the metrics was evaluated. Medication changes and 6-month admissions were compared between this group (post-BSS) and a comparable previous group (pre-BSS). Concordance and regression analyses for all-cause admissions and H E-related admissions were performed, and comparisons were made for HE-related medication stability. In the longitudinal analysis, an outpatient group seen twice was analyzed for BSS and BMs. RESULTS: In the post-BSS cohort, 112 patients were included with only 46% BSS and BMs concordance and modest BSS/BMs correlation (r = 0.27, P = 0.005). Compared with a pre-BSS cohort (N = 114), there was a lower 6-month total (4% vs 0.36%, P< 0.001) or HE-related admission (1% vs 0.12%, P= 0.002). Regression showed model for end-stage liver disease (odds ratio [OR]: 1.10, P= 0.003) and pre-BSS/post-BSS (OR: 0.04, P< 0.001) for all-cause admissions and HE (OR: 3.59, P= 0.04) and preera/postera (OR: 0.16, P = 0.02) for HE-related admissions as significant. HE medication regimens were more stable post-BSS vs pre-BSS (32% vs 20%, P = 0.04), which was due to patients with BSS > BMs (P= 0.02). In the longitudinal analysis, 33 patients without medication changes or underlying clinical status changes were tested 36 +/- 24 days apart. No changes in BSS (P = 0.73) or BMs (P = 0.19) were found. DISCUSSION: BSS is complementary and additive to BM frequency, can modulate the risk of readmissions and stabilize HE-related therapy changes in outpatients with cirrhosis, and could help personalize HE management.
引用
收藏
页码:295 / 300
页数:6
相关论文